Pathophysiology, Clinical Manifestations, and Pharmacological Management of Pruritus in Primary Biliary Cholangitis: A Systematic Review

Authors

  • Retno Dwi Utami Universitas Mataram
  • Nensy Dwi Astika
  • Made Prajnana Adhi Parasikan Susana
  • Florentcia Davina Gunawan
  • Baiq Mayada Isqie
  • Lalu Abdul Mubarok Mubarok
  • Indri Tiffani
  • Ashila Sallama Nur Fadlila
  • Mira Nupila Rahma
  • Wibisono Hasanul Muhtaram
  • Pande Komang Inten Widya Iswara Oka
  • Kurniati
  • Nurhidayati

DOI:

https://doi.org/10.58258/ez7rj885

Abstract

Primary Biliary Cholangitis (PBC) is a chronic autoimmune cholestatic liver disease marked by the progressive destruction of small intrahepatic bile ducts. Chronic pruritus affects about 70-80% of patients, can greatly diminish quality of life, and does not present with primary skin lesions. Its pathogenesis is complicated, and the lack of primary lesion signs continues to make management a clinical challenge. This review aims to discuss the pathophysiology and the effectiveness of current pharmacological therapies for pruritus associated with PBC. Literature searches were carried out using PubMed and ScienceDirect, with keywords relating to PBC, pruritus, and treatment. Only original research articles in English published from 2016 to 2026 were included. In total, 29 studies met the inclusion criteria and were analyzed narratively. Pruritus in PBC involves several mediators, such as bile acids, autotaxin (ATX), lysophosphatidic acid (LPA), interleukin-31 (IL-31), and changes in gut microbiota. Clinically, cholestatic pruritus is usually worse at night, especially on the palms and soles, and occurs without primary skin lesions. Several pharmacological therapies have shown promising results, particularly seladelpar, bezafibrate, cholestyramine, rifampicin, nalfurafine, and inhibitors of the ileal bile acid transporter (IBAT). On the other hand, farnesoid X receptor agonists like obeticholic acid may worsen pruritus for some patients. Pruritus in PBC is a complex and multifactorial clinical problem. Treatments that target bile acid metabolism, the ATX-LPA pathway, pruritogenic cytokines, and the opioid system have shown potential to reduce pruritus intensity and improve quality of life for patients.
Abstract Views 17PDF Downloads 7

References

[1] M. Angelara, K. Papachristou, M. Papatheodoridi, N. Nasiri-Ansari, D. S. Karagiannakis, and T. Androutsakos, “Primary biliary cholangitis. Treatment options in 2025. A narrative review,” Front. Immunol., vol. 16, p. 1698833, Nov. 2025, doi: 10.3389/FIMMU.2025.1698833/TEXT.

[2] T. R. Nietsche, G. Dotta, C. B. Barcaui, and M. L. C. G. Ferraz, “Cholestatic pruritus: a knowledge update,” An. Bras. Dermatol., vol. 97, no. 3, pp. 332–337, May 2022, doi: 10.1016/j.abd.2021.06.007.

[3] S. P. Patel, C. Vasavda, B. Ho, J. Meixiong, X. Dong, and S. G. Kwatra, “Cholestatic pruritus: Emerging mechanisms and therapeutics,” J. Am. Acad. Dermatol., vol. 81, no. 6, pp. 1371–1378, Dec. 2019, doi: 10.1016/J.JAAD.2019.04.035.

[4] M. D. Levitt, S. M. Hapak, and D. G. Levitt, “Alkaline Phosphatase Pathophysiology with Emphasis on the Seldom-Discussed Role of Defective Elimination in Unexplained Elevations of Serum ALP - A Case Report and Literature Review,” Clin. Exp. Gastroenterol., vol. 15, pp. 41–49, 2022, doi: 10.2147/CEG.S345531.

[5] A. Reig, P. Sesé, and A. Parés, “Effects of Bezafibrate on Outcome and Pruritus in Primary Biliary Cholangitis With Suboptimal Ursodeoxycholic Acid Response,” Am. J. Gastroenterol., vol. 113, no. 1, pp. 49–55, 2018, doi: 10.1038/AJG.2017.287.

[6] V. S. Hegade et al., “Effect of ileal bile acid transporter inhibitor GSK2330672 on pruritus in primary biliary cholangitis: a double-blind, randomised, placebo-controlled, crossover, phase 2a study,” The Lancet, vol. 389, no. 10074, pp. 1114–1123, Mar. 2017, doi: 10.1016/S0140-6736(17)30319-7.

[7] V. Kode and K. K. Yimam, “Cholestatic Pruritus: Pathophysiology, Current Management Approach, and Emerging Therapies,” Current Hepatology Reports 2024 23:1, vol. 23, no. 1, pp. 123–136, Feb. 2024, doi: 10.1007/S11901-024-00638-7.

[8] A. E. Kremer et al., “Antipruritic effect of bezafibrate and serum autotaxin measures in patients with primary biliary cholangitis,” Gut, vol. 68, no. 10, pp. 1902–1903, Oct. 2019, doi: 10.1136/GUTJNL-2018-317426.

[9] S. Yan and X. M. Yin, “Gut microbiome in liver pathophysiology and cholestatic liver disease,” Liver Res., vol. 5, no. 3, pp. 151–163, Sep. 2021, doi: 10.1016/J.LIVRES.2021.08.001.

[10] Y. Zhou et al., “Variation in microbiome and metabolites is associated with advantageous effects of cholestyramine on primary biliary cholangitis with pruritus,” Microbiol. Spectr., vol. 14, no. 2, Feb. 2026, doi: 10.1128/SPECTRUM.00747-25;PAGEGROUP:STRING:PUBLICATION.

[11] A. E. Kremer et al., “Seladelpar treatment reduces IL-31 and pruritus in patients with primary biliary cholangitis,” Hepatology, vol. 80, no. 1, pp. 27–37, Jul. 2024, doi: 10.1097/HEP.0000000000000728.

[12] C. L. Bowlus et al., “A phase II, randomized, open-label, 52-week study of seladelpar in patients with primary biliary cholangitis,” J. Hepatol., vol. 77, no. 2, pp. 353–364, Aug. 2022, doi: 10.1016/j.jhep.2022.02.033.

[13] A. E. Kremer et al., “Seladelpar improved measures of pruritus, sleep, and fatigue and decreased serum bile acids in patients with primary biliary cholangitis,” Liver Int., vol. 42, no. 1, pp. 112–123, Jan. 2022, doi: 10.1111/LIV.15039.

[14] G. M. Hirschfield et al., “Seladelpar efficacy and safety at 3 months in patients with primary biliary cholangitis: ENHANCE, a phase 3, randomized, placebo-controlled study.,” Hepatology, vol. 78, no. 2, pp. 397–415, Apr. 2023, doi: 10.1097/HEP.0000000000000395.

[15] J. Pate et al., “Practical strategies for pruritus management in the obeticholic acid-treated patient with PBC: proceedings from the 2018 expert panel,” BMJ Open Gastroenterol., vol. 6, no. 1, Feb. 2019, doi: 10.1136/BMJGAST-2018-000256.

[16] F. Nevens et al., “A Placebo-Controlled Trial of Obeticholic Acid in Primary Biliary Cholangitis,” N. Engl. J. Med., vol. 375, no. 7, pp. 631–643, Aug. 2016, doi: 10.1056/NEJMOA1509840.

[17] K. V. Kowdley et al., “A randomized trial of obeticholic acid monotherapy in patients with primary biliary cholangitis,” Hepatology, vol. 67, no. 5, pp. 1890–1902, May 2018, doi: 10.1002/HEP.29569.

[18] F. Terracciani et al., “Long-term effectiveness, safety, and liver stiffness dynamics of PBC treatment with obeticholic acid in real-world,” JHEP Reports, vol. 7, no. 8, p. 101448, Aug. 2025, doi: 10.1016/J.JHEPR.2025.101448.

[19] M. Trauner et al., “Long-term efficacy and safety of obeticholic acid for patients with primary biliary cholangitis: 3-year results of an international open-label extension study,” Lancet Gastroenterol. Hepatol., vol. 4, no. 6, pp. 445–453, Jun. 2019, doi: 10.1016/S2468-1253(19)30094-9.

[20] D. D’Amato et al., “Real-world experience with obeticholic acid in patients with primary biliary cholangitis,” JHEP Rep., vol. 3, no. 2, Apr. 2021, doi: 10.1016/J.JHEPR.2021.100248.

[21] R. Bolier et al., “Fibrates for the treatment of cholestatic itch (FITCH): study protocol for a randomized controlled trial,” Trials, vol. 18, no. 1, May 2017, doi: 10.1186/S13063-017-1966-8.

[22] C. Corpechot et al., “A Placebo-Controlled Trial of Bezafibrate in Primary Biliary Cholangitis,” N. Engl. J. Med., vol. 378, no. 23, pp. 2171–2181, Jun. 2018, doi: 10.1056/NEJMOA1714519.

[23] E. de Vries et al., “Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies: A Double-Blind, Randomized, Placebo-Controlled Trial,” Gastroenterology, vol. 160, no. 3, pp. 734-743.e6, Feb. 2021, doi: 10.1053/j.gastro.2020.10.001.

[24] F. Carreño, E. Karatza, R. Mehta, J. Collins, D. Austin, and B. Swift, “Population Dose–Response-Time Analysis of Itch Reduction and Patient-Reported Tolerability Supports Phase III Dose Selection for Linerixibat,” Clin. Pharmacol. Ther., vol. 115, no. 2, pp. 288–298, Feb. 2024, doi: 10.1002/CPT.3103;PAGEGROUP:STRING:PUBLICATION.

[25] C. Levy et al., “GLIMMER: A Randomized Phase 2b Dose-Ranging Trial of Linerixibat in Primary Biliary Cholangitis Patients With Pruritus,” Clinical Gastroenterology and Hepatology, vol. 21, no. 7, pp. 1902-1912.e13, Jul. 2023, doi: 10.1016/j.cgh.2022.10.032.

[26] T. Kanda et al., “Pruritus in Chronic Cholestatic Liver Diseases, Especially in Primary Biliary Cholangitis: A Narrative Review,” Int. J. Mol. Sci., vol. 26, no. 5, Mar. 2025, doi: 10.3390/IJMS26051883.

[27] S. Al-Dury et al., “Pilot study with IBAT inhibitor A4250 for the treatment of cholestatic pruritus in primary biliary cholangitis,” Scientific Reports 2018 8:1, vol. 8, no. 1, pp. 6658-, Apr. 2018, doi: 10.1038/s41598-018-25214-0.

[28] K. Zhu, “WCN26-260 NALFURAFINE FOR REFRACTORY UREMIC AND CHOLESTATIC PRURITUS IN A HEMODIALYSIS PATIENT: A CASE REPORT,” Kidney Int. Rep., vol. 11, no. 4, p. 104186, Apr. 2026, doi: 10.1016/j.ekir.2026.104186.

[29] M. Yagi et al., “Is patient-reported outcome improved by nalfurafine hydrochloride in patients with primary biliary cholangitis and refractory pruritus? A post-marketing, single-arm, prospective study,” J. Gastroenterol., vol. 53, no. 10, pp. 1151–1158, Oct. 2018, doi: 10.1007/S00535-018-1465-Z.

[30] Y. Zhang et al., “Ursodeoxycholic acid accelerates bile acid enterohepatic circulation,” Br. J. Pharmacol., vol. 176, no. 16, pp. 2848–2863, Aug. 2019, doi: 10.1111/BPH.14705.

[31] M. Kusaczuk, “Tauroursodeoxycholate—Bile Acid with Chaperoning Activity: Molecular and Cellular Effects and Therapeutic Perspectives,” Cells, vol. 8, no. 12, p. 1471, Dec. 2019, doi: 10.3390/CELLS8121471.

[32] H. Ma et al., “A multicenter, randomized, double-blind trial comparing the efficacy and safety of TUDCA and UDCA in Chinese patients with primary biliary cholangitis,” Medicine (United States), vol. 95, no. 47, 2016, doi: 10.1097/MD.0000000000005391.

[33] E. Wunsch, J. Raszeja-Wyszomirska, O. Barbier, M. Milkiewicz, M. Krawczyk, and P. Milkiewicz, “Effect of S-adenosyl-L-methionine on liver biochemistry and quality of life in patients with primary biliary cholangitis treated with ursodeoxycholic acid. A prospective, open label pilot study,” J. Gastrointestin. Liver Dis., vol. 27, no. 3, pp. 273–279, Sep. 2018, doi: 10.15403/JGLD.2014.1121.273.ICZ.

[34] E. Kilanczyk et al., “S-adenosyl-L-methionine (SAMe) halts the autoimmune response in patients with primary biliary cholangitis (PBC) via antioxidant and S-glutathionylation processes in cholangiocytes,” Biochim. Biophys. Acta Mol. Basis Dis., vol. 1866, no. 11, Nov. 2020, doi: 10.1016/J.BBADIS.2020.165895.

[35] J. M. Schattenberg et al., “A randomized placebo-controlled trial of elafibranor in patients with primary biliary cholangitis and incomplete response to UDCA,” J. Hepatol., vol. 74, no. 6, pp. 1344–1354, Jun. 2021, doi: 10.1016/j.jhep.2021.01.013.

[36] S. M. Post, H. Duez, P. P. Gervois, B. Staels, F. Kuipers, and H. M. G. Princen, “Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregulation of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression,” Arterioscler. Thromb. Vasc. Biol., vol. 21, no. 11, pp. 1840–1845, 2001, doi: 10.1161/HQ1101.098228.

[37] Q. X. Ooi, K. Brendel, S. van Beek, J. A. Zdovc, M. Bardol, and M. Dehez, “Population Pharmacokinetics and Pharmacokinetics-Pharmacodynamics Analyses of Elafibranor to Support Dose Selection in Primary Biliary Cholangitis,” CPT Pharmacometrics Syst. Pharmacol., vol. 15, no. 5, May 2026, doi: 10.1002/PSP4.70247.

[38] C. L. Bowlus et al., “Safety, tolerability, and efficacy of maralixibat in adults with primary sclerosing cholangitis: Open-label pilot study,” Hepatol. Commun., vol. 7, no. 6, p. e0153, Jun. 2023, doi: 10.1097/HC9.0000000000000153.

[39] V. Billo et al., “Carrier cross-reactivities of the bile acid reabsorption inhibitors elobixibat, linerixibat, maralixibat, and odevixibat,” J. Lipid Res., vol. 66, no. 11, Nov. 2025, doi: 10.1016/j.jlr.2025.100910.

[40] M. J. Mayo et al., “A Randomized, Controlled, Phase 2 Study of Maralixibat in the Treatment of Itching Associated With Primary Biliary Cholangitis,” Hepatol. Commun., vol. 3, no. 3, pp. 365–381, Mar. 2019, doi: 10.1002/HEP4.1305.

[41] L. K. Oetjen et al., “Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch,” Cell, vol. 171, no. 1, pp. 217-228.e13, Sep. 2017, doi: 10.1016/j.cell.2017.08.006.

[42] M. R. Mack et al., “Type 2 cytokines sensitize human sensory neurons to itch-associated stimuli,” Front. Mol. Neurosci., vol. 16, p. 1258823, Oct. 2023, doi: 10.3389/FNMOL.2023.1258823/TEXT.

[43] L. A. Evans, A. P. Keaveny, D. M. Harnois, M. G. Heckman, H. J. Sledge, and J. C. Sluzevich, “Efficacy of dupilumab for the treatment of moderate-to-severe chronic hepatic pruritus: An open-label, single-arm, exploratory study,” J. Am. Acad. Dermatol., vol. 94, no. 3, pp. 888–894, Mar. 2026, doi: 10.1016/J.JAAD.2025.11.051.

[44] D. C. Tully et al., “Discovery of Tropifexor (LJN452), a Highly Potent Non-bile Acid FXR Agonist for the Treatment of Cholestatic Liver Diseases and Nonalcoholic Steatohepatitis (NASH),” J. Med. Chem., vol. 60, no. 24, pp. 9960–9973, Dec. 2017, doi: 10.1021/ACS.JMEDCHEM.7B00907.

[45] M. K. Badman et al., “Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of the Novel Non-Bile Acid FXR Agonist Tropifexor (LJN452) in Healthy Volunteers,” Clin. Pharmacol. Drug Dev., vol. 9, no. 3, pp. 395–410, Apr. 2020, doi: 10.1002/CPDD.762.

[46] C. Schramm et al., “Farnesoid X receptor agonist tropifexor attenuates cholestasis in a randomised trial in patients with primary biliary cholangitis,” JHEP Rep., vol. 4, no. 11, Nov. 2022, doi: 10.1016/J.JHEPR.2022.100544.

[47] J. S. Fridman et al., “Selective inhibition of JAK1 and JAK2 is efficacious in rodent models of arthritis: preclinical characterization of INCB028050,” J. Immunol., vol. 184, no. 9, pp. 5298–5307, May 2010, doi: 10.4049/JIMMUNOL.0902819.

[48] J. J. O’Shea, D. M. Schwartz, A. V. Villarino, M. Gadina, I. B. McInnes, and A. Laurence, “The JAK-STAT pathway: impact on human disease and therapeutic intervention,” Annu. Rev. Med., vol. 66, pp. 311–328, Jan. 2015, doi: 10.1146/ANNUREV-MED-051113-024537.

[49] S. C. Gordon et al., “Baricitinib and primary biliary cholangitis,” J. Transl. Autoimmun., vol. 4, Jan. 2021, doi: 10.1016/j.jtauto.2021.100107.

[50] U. Beuers, F. Wolters, and R. P. J. Oude Elferink, “Mechanisms of pruritus in cholestasis: understanding and treating the itch,” Nature Reviews Gastroenterology & Hepatology 2022 20:1, vol. 20, no. 1, pp. 26–36, Oct. 2022, doi: 10.1038/s41575-022-00687-7.

[51] A. E. Kremer et al., “Serum autotaxin is increased in pruritus of cholestasis, but not of other origin, and responds to therapeutic interventions,” Hepatology, vol. 56, no. 4, pp. 1391–1400, Oct. 2012, doi: 10.1002/HEP.25748.

[52] G. J. Webb, S. R. Rahman, C. Levy, and G. M. Hirschfield, “Low risk of hepatotoxicity from rifampicin when used for cholestatic pruritus: a cross-disease cohort study,” Aliment. Pharmacol. Ther., vol. 47, no. 8, pp. 1213–1219, Apr. 2018, doi: 10.1111/APT.14579.

[53] M. J. Mayo et al., “NGM282 for Treatment of Patients With Primary Biliary Cholangitis: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial,” Hepatol. Commun., vol. 2, no. 9, pp. 1037–1050, Sep. 2018, doi: 10.1002/HEP4.1209.

[54] S. A. Harrison et al., “NGM282 Improves Liver Fibrosis and Histology in 12 Weeks in Patients With Nonalcoholic Steatohepatitis,” Hepatology, vol. 71, no. 4, pp. 1198–1212, Apr. 2020, doi: 10.1002/HEP.30590.

[55] Y. Zhou et al., “Variation in microbiome and metabolites is associated with advantageous effects of cholestyramine on primary biliary cholangitis with pruritus,” Microbiol. Spectr., vol. 14, no. 2, Feb. 2026, doi: 10.1128/SPECTRUM.00747-25;PAGEGROUP:STRING:PUBLICATION.

[56] R. S. Golpanian, G. Yosipovitch, and C. Levy, “Use of Butorphanol as Treatment for Cholestatic Itch,” Digestive Diseases and Sciences 2020 66:5, vol. 66, no. 5, pp. 1693–1699, Jun. 2020, doi: 10.1007/S10620-020-06392-2.

Downloads

Published

2026-09-25

Issue

Vol. 7 No. 3 (2026): Research of Service Administration Health and Sains Healthys (September)

Section

Articles

License

Authors who publish with Research of Service Administration Health and Sains Healthys agree to the following terms:

  1. Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License (CC BY-SA 4.0) that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal. 
  2. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work.

How to Cite

Pathophysiology, Clinical Manifestations, and Pharmacological Management of Pruritus in Primary Biliary Cholangitis: A Systematic Review. (2026). Research of Service Administration Health and Sains Healthys, 7(3), 282-301. https://doi.org/10.58258/ez7rj885